• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nuwellis Inc.

    5/6/24 4:01:02 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email
    SC 13G 1 shn_13g.htm SCHEDULE 13G

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Nuwellis, Inc.
    (Name of Issuer)
     
    Common stock, par value $0.0001
    (Title of Class of Securities)
     
    67113Y405
    (CUSIP Number)
     
    April 26, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     
     

     

     

    CUSIP No. 67113Y405   13G   Page 2 of 5 Pages

     

    1  NAME OF REPORTING PERSONS
       
      S.H.N. Financial Investments Ltd.
    2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
     

     

    (a)  ☐

      (b)  ☐
    3 SEC USE ONLY
       
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Israel 
      5                  SOLE VOTING POWER
         
        1,041,668 (1)(2)(3)
    NUMBER OF 6 SHARED VOTING POWER
    SHARES    
    BENEFICIALLY    0
    OWNED BY 7 SOLE DISPOSITIVE POWER
    EACH REPORTING    
    PERSON WITH   1,041,668 (1)(2)(3)
      8 SHARED DISPOSITIVE POWER
         
        0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      1,041,668 (1)(2)(3)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     

     

    ☐

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      5.7% (3)
    12 TYPE OF REPORTING PERSON
     

     

    OO (4)

           

     

      (1) Represents shares of the Issuer’s Common Stock purchased by the Reporting Person.

     

      (2) Does not include 1,562,502 common warrants to purchase 1,562,502 shares of the Issuer’s Common Stock, which is subject to a 4.99% beneficial ownership limitation.

     

      (3) Based upon 18,051,443 shares of Common Stock outstanding based on the Issuer’s Rule 424(b)(4) Prospectus filed with the Securities and Exchange Commission on April 29, 2024.

     

      (4) The Reporting Person has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b).

     

     

     

     

     
     

     

    CUSIP No.  67113Y405   13G   Page 3 of 5 Pages

     

    Item 1. Security and Issuer.

     

      (a) Name of Issuer:

     

    Nuwellis, Inc.

     

     

    (b)

     

    Address of Issuer:

     

    12988 Valley View Road

    Eden Prairie, Minnesota 55344

     

    Item 2. Identity and Background.

     

    (a)  Name of Person Filing:
       
      S.H.N. Financial Investments Ltd.
       
    (b)   Address of Principal Business Office or, if none, Residence:
       
     

    Herzliya Hills

    Arik Einstein 3, Israel, 4610301

       
    (c) Citizenship or Place of Organization:
       
      Israel
       
    (d) Title of Class of Securities:
       
      Common Stock, par value $0.0001 per share.
       
    (e)  CUSIP Number:
       
      67113Y405

     

    Item 3.

     

    Not applicable.

     

     

     

     
     

     

     

    CUSIP No. 67113Y405   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

      (a) The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

      (b) The percentage set forth on Row (11) of the cover page for the reporting person is based upon 18,051,443 shares of Common Stock outstanding based on the Issuer’s Rule 424(b)(4) Prospectus filed with the Securities and Exchange Commission on April 29, 2024.

     

      (c) Nir Shamir is the Chief Executive Officer of SHN. As such, SHN and Mr. Shamir may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities described herein. To the extent Mr. Shamir is deemed to beneficially own such securities, Mr. Shamir disclaims beneficial ownership of these securities for all other purposes.

      

    Item 5.

    Ownership of 5 Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

     

     
    CUSIP No.  67113Y405   13G   Page 5 of 5 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

       
      By:    S.H.N. Financial Investments Ltd.
         
    May 6, 2024 By: /s/ Nir Shamir
        Nir Shamir, Chief Executive Officer

     

     

     

     

     

     

     

     

     

    Get the next $NUWE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care Settings

    MINNEAPOLIS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today announced the presentation of new real-world data from New York City's Lenox Hill Hospital at the 2025 American Society of Nephrology (ASN) Kidney Week, reinforcing the versatility of Aquadex® ultrafiltration therapy in patients with acute kidney injury (AKI) and complex fluid management needs. The retrospective analysis, titled "Diversifying Aquapheresis Applications in Critical Care: Nephrology-Led Institutional Experience" (Presentation

    12/9/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Continues Clinician-Driven Growth in Pediatric Care with a Leading Hospital in the Northeast U.S.

    MINNEAPOLIS, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today that a leading Northeastern U.S. children's hospital has initiated an Aquadex Ultrafiltration Program. Pediatric nephrology and cardiology teams across the country continue to seek out the therapy for its minimal extracorporeal volume requirement and reliability in managing fluid-sensitive patients, driving steady growth in Nuwellis' expanding pediatric market. Aquadex adoption continues to accelerate in high-acuity pediatric settings nationwide. Children's hospitals are integrating the therap

    12/4/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum

    MINNEAPOLIS, MN, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today reported financial results for the third quarter ended September 30, 2025 and provided a business update on recent milestones advancing the company's cardiorenal growth strategy. Third Quarter 2025 Highlights Total revenue of $2.2 million, down 6% year-over-year and up 29% sequentially, reflecting increased consumable utilization and stronger U.S. console sales on a sequential quarter basis. On a pro-forma basis, revenue grew approxima

    11/12/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    SEC Filings

    View All

    SEC Form 10-Q filed by Nuwellis Inc.

    10-Q - Nuwellis, Inc. (0001506492) (Filer)

    11/12/25 4:19:12 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    11/12/25 11:49:33 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Leadership Update

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    10/8/25 5:10:35 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Nuwellis with a new price target

    ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

    7/29/24 7:42:07 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Erb John L

    4 - Nuwellis, Inc. (0001506492) (Issuer)

    7/1/25 8:30:33 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CEO and President Erb John L converted options into 1,100,022 shares (SEC Form 4)

    4 - Nuwellis, Inc. (0001506492) (Issuer)

    6/11/25 8:43:36 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Mcdonald David

    4 - Nuwellis, Inc. (0001506492) (Issuer)

    5/21/25 4:59:22 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025

    MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that it will release financial results for the third quarter 2025 on November 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-274-8461 (U.S) or 1-203-51

    10/23/25 9:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Postpones Second Quarter 2025 Earnings Release and Conference Call to August 14, 2025

    MINNEAPOLIS, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on fluid management, today announced that it will postpone its 2025 second quarter earnings release and conference call, originally scheduled for August 12, 2025. The Company requires additional time to complete its valuations and for its audit firm to complete its related audit procedures. There are no current disagreements with Baker Tilly US, LLP, the Company's auditor. The Company expects to host a conference call and webcast at 9:00 AM ET on August 14, 2025 to discuss its financial results and provide a general business update. To access the live webcast, please visit the

    8/6/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025

    MINNEAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the second quarter 2025 on August 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-245-3047 (U.S) or 1-203-518-9765 (international) and using the conference ID: NUWEQ2. A

    7/22/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints John Erb as Chief Executive Officer

    WHOWHATWHEREWHENHOWJohn ErbAppointed as Chief Executive Officer (no longer serving in an interim capacity)Nuwellis HeadquartersEffective June 27, 2025Appointment confirmed by the Board of Directors following his interim leadership MINNEAPOLIS, July 02, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to advancing solutions in fluid management, today announced the appointment of John Erb as its Chief Executive Officer. Erb, who has served as interim CEO since February 2025, will continue to lead the company with a focus on strategic clarity, operational discipline, and sustainable growth. This marks Erb's return to the CEO role at Nuwellis, havi

    7/2/25 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

    MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim President and Chief Executive Officer and assumed all of the duties formerly performed by Mr. Jaramillo. Nuwellis intends to retain an executive search firm to assist in identifying a permanent CEO. Mr. Erb, stated, "Nestor has been with the company for nearly si

    2/24/25 4:05:00 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Announces Board of Directors Transition

    MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience

    11/1/23 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/30/24 4:11:06 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    8/2/24 4:12:11 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Nuwellis Inc.

    SC 13G - Nuwellis, Inc. (0001506492) (Subject)

    5/6/24 4:01:02 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care